☰

Emulate Inc.

From bespoke research tool to standardized biotech infrastructure

Industry
Organ-on-Chip Technology and Microphysiological Systems
Headquarters
Boston, Massachusetts, United States
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Emulate Inc.'s published strategy and is not endorsed by, or produced in cooperation with, Emulate Inc.. Company website

Strategic priorities

Emulate launched the AVA Emulation System in mid-2025, a self-contained Organ-on-Chip workstation that runs up to 96 chips per batch — an eight-fold throughput step over the prior Zoë-CM2 — with greater than 30,000 automated data points per week and hands-on labour reduced by more than 50 percent. The platform positions the company as infrastructure for the pharma industry's move from bespoke research tools to standardized biotech scale, and it sits alongside the September 2024 Chip-R1 Rigid Chip launch that resolved the long-standing PDMS (polydimethylsiloxane) drug-absorption problem for ADME and toxicology work.

Regulatory acceptance sits at the centre of the strategy. Emulate's Liver-Chip performance study, published in Communications Medicine in 2023, reported 87 percent sensitivity for hepatotoxicity signals against drugs that had passed animal testing, with 100 percent specificity. The follow-on Cooperative Research and Development Agreement (CRADA) with the FDA is the path to formal acceptance of Organ-Chip data in Investigational New Drug (IND) submissions. The economic case the company publishes frames that as $3 billion per year of pharma R&D value once integrated earlier in the pipeline.

The operating model is still small: headcount between 81 and 119 across 2024 to early 2026, with funding in the $225 million to $352 million range across the Series A through Series E rounds and grants, the largest being the August 2021 Series E of $82 million led by Perceptive Advisors and Northpond Ventures. The customer base is concentrated in the top tier of pharmaceutical and academic research institutions, served from the Boston facility.

Three operational trajectories shape the next 18 months. AVA has to be accepted as a routine platform by pharmaceutical users, which means data has to flow into their LIMS (Laboratory Information Management System) and AI (Artificial Intelligence) pipelines rather than sitting in Emulate's software. The CRADA validation work has to produce publishable evidence that holds up in a regulatory submission. And the workforce has to scale from 81-119 specialists to the level required to support dozens of AVA installations concurrently — a profile that the company itself identifies as a barrier, with 57 percent of laboratories citing knowledge gaps as the reason for not adopting microphysiological systems (MPS).

Challenges we see

  • Digital Integration

    Connecting heterogeneous laboratory equipment into one data estate

    Pharmaceutical and academic customers operate fragmented ecosystems of equipment from different eras and manufacturers, including microfluidic controllers, imaging systems and laboratory instruments that publish in vendor-specific formats. The IT/OT (Information Technology / Operational Technology) convergence required to bring them into a central LIMS or cloud data lake depends on standardized protocols such as OPC UA (Open Platform Communications Unified Architecture) and MQTT (a lightweight publish/subscribe messaging protocol commonly used for sensor data), which are not yet universal in biotech research.

    Where Organ-Chip runs sit alongside instruments that each publish in their own format, the picture of an experiment lives in as many places as there are instruments, so the answer to a cross-asset question is assembled after the run rather than available during it.

  • Data Data

    Keeping multi-modal AVA data queryable for AI pipelines

    A typical 7-day AVA run produces millions of data points spanning real-time imaging, automated effluent assays and post-takedown omics. Emulate positions AVA as 'AI-ready' and the data as a 'rich, multi-modal foundation' for machine-learning pipelines for target discovery and lead optimization.

    Where imaging, effluent and omics data are timestamped against the same biological event but live in separate stores, the data scientist has to reconcile the schemas before a model can be trained, which moves data engineering upstream of every question the platform is meant to answer.

  • Compliance Regulatory

    Standing up ALCOA+ electronic records for regulated use

    For Organ-Chip data to be used in regulatory filings it must adhere to ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, Available). Many customer laboratories still move between paper-based and digital logging as the workload shifts.

    Where lab results move between paper, spreadsheet and LIMS by hand, the evidence that an Organ-Chip run was performed as recorded is reconstructed after the run, and the review path rather than the science sets the calendar for a regulated submission.

  • Digital Operations

    Closing the laboratory skill gap for MPS workflows

    Emulate has identified a workforce skill gap as a barrier to adoption of microphysiological systems, with 57 percent of laboratories citing lack of knowledge as the reason they have not adopted MPS technology. Operating Organ-Chips competently requires expertise in microfluidics, cell culture, imaging and data analysis.

    Where the operator profile for a new technology has to grow from a small specialist population to a routine lab skill, the path from expert-dependent to peer-reviewed execution sits on whether the workflow itself can be made legible to a non-specialist.

  • Operations Manufacturing

    Scaling the Chip-R1 rigid-chip consumable line alongside the AVA rollout

    The Chip-R1 Rigid Chip, launched September 2024, is built from low-drug-absorbing polycarbonate rather than the historically standard PDMS, resolving the absorption problem for lipophilic compounds in ADME (Absorption, Distribution, Metabolism, and Excretion) and toxicology work. Scaling the polycarbonate consumable line to support AVA's 96-chip batches is now a load-bearing step in the platform's commercial ramp.

    Where a new consumable material carries the resolution of a long-standing scientific friction, the production line that makes it has to be reachable from the same quality system as the workstation, so that lot-level evidence moves with the chip rather than being assembled at the receiving site.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Connecting laboratory equipment to a shared data estate

    Customer laboratories running Organ-Chip work alongside instruments that publish in vendor-specific formats, creating manual entry requirements and 'dark data' pockets that limit the value the AVA platform can deliver.

    Connecting microfluidic controllers, imaging systems and laboratory instruments through OPC UA and MQTT into a shared LIMS and cloud data lake lets Organ-Chip results sit alongside the rest of the laboratory's evidence rather than beside it.

    • Emulate Launches AVA Emulation System, 2025
    • Emulate 2024-2025 strategic communication, FDA Modernization Act 2.0 alignment

  2. Putting multi-modal AVA data into a queryable model

    AVA generates millions of timestamped data points per run across imaging, effluent and omics streams. The published value proposition rests on those streams feeding machine-learning pipelines, but the data currently sits across separate stores with their own schemas.

    An ontology-driven data model for assay, chip, run, image, effluent and omics entity types lets AVA's output load against a single schema, so a query written once returns the combined evidence from imaging, effluent and omics rather than a stitched view.

    • Emulate AVA Emulation System launch, 2025
    • Emulate Liver-Chip performance framework, Communications Medicine, 2023

  3. Producing audit-ready electronic records for regulated workflows

    For Organ-Chip data to be used in regulatory filings it must meet ALCOA+ principles, and many customer laboratories are mid-transition from paper-based logging to digital systems.

    Connecting laboratory instruments to a Laboratory Execution System (LES) so results are captured at the source with their own audit trail takes transcription out of the regulated workflow and shortens the path from run to filing.

    • Emulate strategic communication on ALCOA+ and GxP (Good "x" Practice) readiness
    • Communications Medicine Liver-Chip publication, 2023

  4. Building a digital operator profile for AVA workflows

    Emulate has identified a 57 percent laboratory knowledge gap as a barrier to MPS adoption, and operating Organ-Chips competently today requires expertise in microfluidics, cell culture, imaging and data analysis.

    A role-based onboarding path with progressive milestones, intuitive dashboards and step-by-step in-software guidance widens the operator population from a small specialist base to a routine laboratory skill.

    • Emulate AVA Emulation System launch, 2025
    • Emulate on the workforce skill gap for MPS technology

  5. Drafting CRADA validation reports and IND submission sections from run records

    The FDA CRADA validation work and the IND submission sections that follow produce a recurring document-assembly load that the existing team handles by hand, with every deviation, change and method update re-entered into a regulatory document.

    Narrow agents draft CRADA validation reports, IND submission sections and standard response documents from the underlying AVA and LIMS records, with a named scientist approving every output before it enters the review queue.

    • Emulate-FDA CRADA, ongoing
    • Communications Medicine Liver-Chip publication, 2023

What we'd propose

  • Digital Lab

    Laboratory equipment integration for AVA installations

    We connect each customer's microfluidic controllers, imaging systems and laboratory instruments through OPC UA and MQTT into a shared LIMS and cloud data lake, so the AVA run sits in the same evidence trail as the rest of the laboratory.

    • Equipment data acquisition

      Getting data off the instruments

      Connect microfluidic controllers, imaging systems and laboratory instruments through OPC UA (Open Platform Communications Unified Architecture) and MQTT so process and result data leave each instrument in a documented, vendor-neutral form rather than staying inside a controller.

    • Unified laboratory data layer

      One place for Organ-Chip results

      Build a shared data layer for the laboratory that holds Organ-Chip runs, associated assay results and instrument metadata under one schema, so a scientist can query across the data estate rather than reconciling per report.

    • AVA-to-LIMS event mapping

      Mapping AVA events to records

      Map the events AVA publishes (run start, image capture, effluent collection, takedown) to the corresponding records in the LIMS, so the laboratory's existing review and release workflows handle Organ-Chip data the same way they handle any other analytical result.

    • Organ-Chip results sit in the same evidence trail as the rest of the laboratory.
    • Manual entry requirements are reduced to the cases that genuinely need human judgement.
    • New laboratory instruments attach to the same shared layer rather than adding another silo.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    Ontology-driven data platform for AVA multi-modal output

    An ontology-based data platform for AVA's imaging, effluent and omics streams, with one schema across assay, chip, run, image, effluent and omics so machine-learning pipelines train on the combined evidence.

    • Shared AVA ontology

      One set of named entities

      Define assay, chip, run, image, effluent and omics as explicit entities with agreed relationships, so a query written once returns the combined evidence from imaging, effluent and omics instead of three dialects of the same table.

    • Multi-modal pipelines

      Loading all three streams

      Build ingestion for real-time imaging, automated effluent assays and post-takedown omics, with timestamp alignment at the boundary so the three streams line up against the same biological event without a per-question reconciliation step.

    • AI-ready query layer

      Questions answered from the data

      Expose the model through a query layer so the customer's data science team can pull training datasets and the company's commercial team can pull study summaries without commissioning a new extract for each question.

    • Three data streams load against one schema instead of three per-assay integrations.
    • Machine-learning pipelines train on combined evidence rather than on a single modality.
    • New assay types attach to the ontology instead of triggering a fresh integration project.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    ALCOA+ Laboratory Execution System for regulated Organ-Chip work

    An LES (Laboratory Execution System) implementation that captures Organ-Chip and adjacent laboratory results at the source with their own audit trail, so the data that goes into a regulatory filing is generated by the run rather than compiled for it.

    • Instrument-level result capture

      Results captured at the source

      Connect balances, plate readers, imaging systems and effluent analysers so results are captured with instrument identity, method version and timestamp attached, instead of being read off a screen and typed into a spreadsheet.

    • LES-to-LIMS event flow

      Sample to result to LIMS

      Map the LES sample and result records onto the LIMS batch and run records, so a deviation or change-control action can be traced back to the specific analytical run that produced the underlying number.

    • 21 CFR Part 11 audit trail

      Electronic records that hold up

      Implement electronic signature, versioning and audit-trail handling to 21 CFR Part 11 (the U.S. Code of Federal Regulations title 21 part 11 — electronic records and electronic signatures), so the evidence chain stands on its own during an inspection.

    • Fewer manual transfers between the instrument and the batch record, and fewer of them to verify.
    • Inspection questions are answered from the record itself rather than from a reconstruction.
    • The same LES handles non-regulated and GxP workflows from one operator surface.

    We've done this before

    See how we do Digital Lab
  • Digital Lab

    Digital operator onboarding for AVA workflows

    A role-based onboarding path with progressive milestones, intuitive dashboards and step-by-step in-software guidance that widens the operator population from a small specialist base to a routine laboratory skill.

    • Role-based learning paths

      Progressive milestones by role

      Build separate onboarding tracks for cell-culture scientists, microfluidic engineers, imaging specialists and data analysts, each with progressive milestones that take the operator from supervised run to independent execution.

    • In-software guided workflows

      Step-by-step in the AVA software

      Surface the operating procedure inside the AVA software at the point of execution, with contextual help and decision prompts so a new operator follows the same path as a specialist without leaving the run.

    • Operator competence analytics

      Readiness visible to the manager

      Track milestone completion, run success and deviation rate per operator so the laboratory manager has a current view of who is ready for independent runs and who is still under supervised execution.

    • New operators reach independent runs in fewer weeks.
    • Specialist time is released from supervised execution to higher-value work.
    • Workforce readiness is visible to the laboratory manager rather than inferred.

    We've done this before

    See how we do Digital Lab
  • Agents

    AI agents for CRADA validation and IND submission documents

    Narrow, reviewable agents that draft the recurring parts of CRADA validation reports and IND submission sections from the underlying AVA and LIMS records, with a named scientist approving every output before it enters the regulatory review queue.

    • Drafting from run and LIMS records

      First drafts from system data

      Generate the first draft of a CRADA validation report, an IND submission section or a standard response document directly from the underlying AVA run records and LIMS data, so the author edits and judges rather than assembles.

    • Template and completeness checking

      Gaps found before review

      Check a submitted document against its template and the relevant regulatory framework, returning missing or inconsistent sections before the document enters the human review queue.

    • Change impact across the document set

      Which documents a change touches

      When a method, specification or standard changes, retrieve every CRADA report and IND section that references it and rank them by how directly they are affected, so the update scope is known on day one.

    • The recurring CRADA and IND document queue is produced from records rather than assembled by hand.
    • Review queues move faster because documents arrive complete and source-traceable.
    • Every output is traceable to the run records it came from and signed off by a named scientist.

    We've done this before

    See how we do Agents

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Emulate Inc.'s own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data interoperability 65 → 92
AVA is designed as 'AI-ready' and generates greater than 30,000 automated data points per week, but pharmaceutical and academic customers run alongside instruments that publish in vendor-specific formats, so the multi-modal streams are timestamped and internally consistent rather than joined to the surrounding laboratory estate.
Process automation 75 → 90
The AVA platform reduces hands-on labour by greater than 50 percent compared with the Zoë-CM2 and is the first workstation to integrate culture, microfluidic control, environmental regulation and real-time imaging, which puts the current state above most research-grade laboratory automation and below the 'lights-out' autonomous target.
Asset connectivity 55 → 85
The IT/OT convergence required to bring Organ-Chip runs into a customer's LIMS and cloud data lake depends on protocols that are not yet universal in biotech research, which leaves a connectivity gap between the AVA workstation and the surrounding laboratory.
Regulatory readiness 60 → 88
The CRADA with the FDA and the 2023 Communications Medicine publication provide a published framework, and the 87 percent Liver-Chip sensitivity against 100 percent specificity sets the bar for IND-grade evidence, but most customer laboratories are still mid-transition from paper-based logging to digital records.
Workforce digital skills 45 → 82
Emulate has identified a 57 percent laboratory knowledge gap as a barrier to MPS adoption, and operating Organ-Chips competently today still requires expertise in microfluidics, cell culture, imaging and data analysis that is documented to be in shortage.
Cybersecurity posture 55 → 85
Connecting AVA into a customer LIMS and cloud data lake puts Organ-Chip run data on the same network as laboratory records, and the security posture around that boundary is not described publicly, so it sits on the design list rather than the public record.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Emulate Inc., and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].